ConductScience.org, home

Paper19903552

Chapter 6 - Solid lipid nanoparticle formulations pharmacokinetic and biopharmaceutical aspects in drug delivery.

Souto EB and 1 other. Methods Enzymol, 2009. Cited by 60 papers, by iCite.

Cite this record

ConductScience Library. Chapter 6 - Solid lipid nanoparticle formulations pharmacokinetic and biopharmaceutical aspects in drug delivery. Papers, record 19903552. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19903552

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Chapter 6 - Solid lipid nanoparticle formulations pharmacokinetic and biopharmaceutical aspects in drug delivery.
PubMed
Journal
Methods Enzymol
PubMed
Year
2009
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
60
iCite
Relative citation ratio, by iCite
2.31
iCite
Revised in PubMed
2009-11-11
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Souto EBEliana B
2Doktorovová SSlavomira

Source PubMed

Download CSV of authors

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Chemistry, PharmaceuticalMajor topic
LipidsMajor topic
NanoparticlesMajor topic
Drug Administration Routes
Drug Delivery Systems

Cited by24

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 60 citations.

PMIDTitleJournalYearIn PapersSource
42328129Overcoming Biological Barriers: A Comprehensive Review of Advanced Melatonin Delivery Systems for Therapeutic Applications.Int J Med Sci2026https://conductscience.org/library/papers/42328129PubMed
40115494Near-Infrared-Triggered Reversible Transformations of Gold Nanorod-Laden Lipid Assemblies: Implications for Cellular Delivery.ACS Appl Nano Mater2022https://conductscience.org/library/papers/40115494PubMed
39959643Psoriasis: Unraveling Disease Mechanisms and Advancing Pharmacological and Nanotechnological Treatments.J Inflamm Res2025https://conductscience.org/library/papers/39959643PubMed
39065795Advances in Nanomedicine for Precision Insulin Delivery.Pharmaceuticals (Basel)2024https://conductscience.org/library/papers/39065795PubMed
38931816Unlocking the Potential of Oleanolic Acid: Integrating Pharmacological Insights and Advancements in Delivery Systems.Pharmaceutics2024https://conductscience.org/library/papers/38931816PubMed
38685805Evaluation of Melatonin and its Nanostructures Effects on Skin Disorders Focused on Wound Healing.Mini Rev Med Chem2024https://conductscience.org/library/papers/38685805PubMed
37504455Solid Lipid Nanoparticles Embedded Hydrogels as a Promising Carrier for Retarding Irritation of Leflunomide.Gels2023https://conductscience.org/library/papers/37504455PubMed
36839978Current Advances in Lipid Nanosystems Intended for Topical and Transdermal Drug Delivery Applications.Pharmaceutics2023https://conductscience.org/library/papers/36839978PubMed
35983586The role of size in PEGylated liposomal doxorubicin biodistribution and anti-tumour activity.IET Nanobiotechnol2022https://conductscience.org/library/papers/35983586PubMed
35845934Anti-CD44 and EGFR Dual-Targeted Solid Lipid Nanoparticles for Delivery of Doxorubicin to Triple-Negative Breast Cancer Cell Line: Preparation, Statistical Optimization, and In Vitro Characterization.Biomed Res Int2022https://conductscience.org/library/papers/35845934PubMed
35198788Physicochemical and biopharmaceutical aspects influencing skin permeation and role of SLN and NLC for skin drug delivery.Heliyon2022https://conductscience.org/library/papers/35198788PubMed
34830774Lipid Nanocarriers for Hyperproliferative Skin Diseases.Cancers (Basel)2021https://conductscience.org/library/papers/34830774PubMed
34200947Melatonin-Loaded Nanocarriers: New Horizons for Therapeutic Applications.Molecules2021https://conductscience.org/library/papers/34200947PubMed
34067151Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics.Int J Mol Sci2021https://conductscience.org/library/papers/34067151PubMed
33391000Research Progress and Prospect of Nanoplatforms for Treatment of Oral Cancer.Front Pharmacol2020https://conductscience.org/library/papers/33391000PubMed
32635279Properties, Extraction Methods, and Delivery Systems for Curcumin as a Natural Source of Beneficial Health Effects.Medicina (Kaunas)2020https://conductscience.org/library/papers/32635279PubMed
32244858Nanomedicines for the Delivery of Antimicrobial Peptides (AMPs).Nanomaterials (Basel)2020https://conductscience.org/library/papers/32244858PubMed
32093358(+)-Limonene 1,2-Epoxide-Loaded SLNs: Evaluation of Drug Release, Antioxidant Activity, and Cytotoxicity in an HaCaT Cell Line.Int J Mol Sci2020https://conductscience.org/library/papers/32093358PubMed
31756981Nanoparticle Delivery Systems in the Treatment of Diabetes Complications.Molecules2019https://conductscience.org/library/papers/31756981PubMed
29844731Newly developed controlled release subcutaneous formulation for tramadol hydrochloride.Saudi Pharm J2018https://conductscience.org/library/papers/29844731PubMed

See all 24 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/19903552

GET https://conductscience.org/api/papers/v1/19903552/cited_by?page=2